TAUNS Laboratories, Inc.
197A.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$55.14B
Close$
Share Statistics
| Market cap | $55.14 Billion |
|---|---|
| Enterprise Value | $72.88 Billion |
| Dividend Yield | $28.00 (5.41%) |
| Earnings per Share | $52.28 |
| Beta | 0.68 |
| Outstanding Shares | 105,508,000 |
Return
| Return on Equity | 28.30% |
|---|---|
| Return on Assets | 12.32% |
| Return on Invested Capital | 14.34% |
Valuation & Multiples
| P/E Ratio | 9.89 |
|---|---|
| PEG | -0.97 |
| Price to Sales | 3.81 |
| Price to Book Ratio | 2.82 |
| Enterprise Value to Revenue | 5.07 |
| Enterprise Value to EBIT | 17.31 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 1.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.34 B
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.80 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About TAUNS Laboratories, Inc.
271 employees
CEO: Masaki Nonaka TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export...